Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Life Sciences Firm Partners to Develop, Sell Canine Supplement
News Update

Share on Stocktwits


The product contains the firm's OxC-beta™ supplement.

Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced in a news release that Dr. Tobias Dog Chews containing its OxC-Beta™ additive are available on Amazon and in the U.S.

The Dr. Tobias brand is run by Mimi's Rock Corp., an online dietary supplement and wellness firm.

"We've been working closely with the Avivagen team to launch the first Dr Tobias branded product into the companion pet market in the United States. With an ever-expanding companion pet market, we believe that our existing Dr Tobias customers will embrace the opportunity to provide the same high standards in supplements and vitamins to their dogs," said Dave Kohler, CEO of Mimi's Rock Corp."

"We're very excited to bring our high quality supplement for companion animals to this important and growing $10 billion per year market," Avivagen CEO Kym Anthony said in the release. "We believe the combination of Avivagen's OxC-beta technology with Mimi's Rock's expertise in online sales and customer service is a win-win scenario for both enterprises, and look forward to building upon this partnership."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe